Another weight loss drug – Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) was recently approved by the U.S. Food and Drug Administration as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Contrave for weight loss available in Philadelphia
Indications for Contrave
Contrave is indicated in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
What is Contrave?
Contrave is a combination of two FDA-approved drugs that have been on the market for quite sometime and are generic – naltrexone and bupropion, in an extended-release formulation. the first component, Naltrexone is approved to treat alcohol and opioid dependence while the second component is a popular antidepressant and smoking cessation drug called Bupropion(Wellbutrin).
How effective is contrave for weight loss?
In one clinical study with about 4,500 obese and overweight patients with and without significant weight-related conditions (non-diabetics) treated for one year showed that patients had an average weight loss of 4.1 percent over treatment with placebo (inactive pill). In this study, 42 percent of patients treated with Contrave lost at least 5 percent of their body weight compared with 17 percent of patients treated with placebo.
A bit slower weight loss in those with diabetes
Results from another study of patients with type 2 diabetes showed that patients had an average weight loss of 2 percent over treatment with placebo at one year. In this study, 36 percent of patients treated with Contrave lost at least 5 percent of their body weight compared with 18 percent of patients treated with placebo.
12 week trial and re-evaluate
Patients taking Contrave at the maintenance dose should be evaluated after 12 weeks to determine if the treatment is effective. If a patient has not lost at least 5 percent of baseline body weight,Contrave should be discontinued, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
Standard boxed warning due to Bupropion (Although not very significant clinically)
Because Contrave contains bupropion, it has a boxed warning to alert health care professionals and patients to the increased risk of suicidal thoughts and behaviors associated with antidepressant drugs. The warning notes that serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation and that it can cause seizures and must not be used in patients who have seizure disorders. The risk of seizure is dose-related and Contrave should be discontinued and not restarted in patients who experience a seizure while being treated with Contrave.
Precautions and Contra-indications of Contrave
Contrave can also raise blood pressure and heart rate and must not be used in patients with uncontrolled high blood pressure. The clinical significance of the increases in blood pressure and heart rate observed with Contrave treatment is unclear, especially for patients with heart-related and cerebrovascular (blood vessel dysfunction impacting the brain) disease, since patients with a history of heart attack or stroke in the previous six months, life-threatening arrhythmias, or congestive heart failure were excluded from the clinical trials. Blood pressure and pulse should be measured prior to starting the drug and should be monitored at regular intervals, particularly among patients with controlled high blood pressure prior to treatment.
Other products containing bupropion should not be taken along with Contrave. The drug should not be used in patients who have eating disorders (bulimia or anorexia nervosa). Contrave should also not be taken by patients who are using opioids or treatments for opioid dependence, or who are experiencing acute opiate withdrawal. Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates and antiepileptic drugs should not take Contrave. Women who are pregnant or trying to become pregnant should not take Contrave.
Side Effects of Contrave
The most common adverse reactions reported with Contrave include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.
Comparison of Contrave to other weight loss drugs
Contrave with an expected 5% weight loss per year compares favorably with the other new weight loss medication, Belviq with 3% weight loss although a bit less than 9% seen in Qsymia (Phentermine and Topiramate). From a cost perspective, Contrave compares very well with both as it only costs $45.00-$75.00 per month as opposed to $150.00-225.00 for Qsymia or Belviq.
Locations for Physicians that can prescribe Contrave
W8MD Medical Weight Loss Center’s physicians are familiar with Contrave and other new and traditional weight loss medications and can offer these and other valuable tools to eligible patients fighting the epidemic of obesity, overweight status!
Philadelphia Insurance Weight Loss & Sleep Center: 1718, Welsh Rd, Philadelphia, PA, 19115 Ph: 1-215-676-2334
King Of Prussia Weight Loss & Sleep Center: 987 Old Eagle School Rd, Ste 712, Wayne, PA, 19087 Ph: 215-676-2334
NYC Insurance Weight Loss & Sleep Center: 2003, Bath Avenue, Brooklyn, NY, 11214 Ph: 1-718-946-5500.
W8MD weight loss program now in New Jersey!
W8MD medical weight loss centers of America’s program at Vida Sleep Center of Dr. Felix Roque’s office at 543, 45th Street, Union City, New Jersey. 543 45th St, Union City, NJ 07087. Phone: (201) 766-6469. This center bills out of network for insurance.
Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California.
Related links on Contrave for weight loss